We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10.11%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$47.1B
AUM Growth
+$2.61B
(+5.9%)
Cap. Flow
-$501M
Cap. Flow
% of AUM
-1.06%
Top 10 Holdings %
Top 10 Hldgs %
14.43%
Holding
3,576
New
705
Increased
706
Reduced
825
Closed
988
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Walmart Inc
WMT
|
+$417M |
| 2 |
Meta Platforms (Facebook)
META
|
+$383M |
| 3 |
Amazon
AMZN
|
+$308M |
| 4 |
Microsoft
MSFT
|
+$293M |
| 5 |
GE Aerospace
GE
|
+$263M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Cigna
CI
|
+$312M |
| 2 |
Bank of America
BAC
|
+$292M |
| 3 |
ExxonMobil
XOM
|
+$274M |
| 4 |
lululemon athletica
LULU
|
+$238M |
| 5 |
Qualcomm
QCOM
|
+$228M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.05% |
| 2 | Technology | 14.35% |
| 3 | Consumer Discretionary | 13.97% |
| 4 | Financials | 9.9% |
| 5 | Industrials | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Boston Properties
BXP
$11B
| $23.7M | 0.05% |
437,485
-693,818
| -61% | -$45.3M |
|
402
Blackbaud
BLKB
$1.5B
| $23.5M | 0.05% |
339,471
+296,571
| +691% | +$17.8M |
|
|
OKLO
403
Oklo
OKLO
$7B
| $23.3M | 0.05% |
2,300,339
| – | – |
|
|
LUCK
404
Lucky Strike Entertainment
LUCK
$938M
| $23.3M | 0.05% |
1,376,707
+500,001
| +57% | +$7.41M |
|
405
Royal Caribbean
RCL
$78.7B
| $23.3M | 0.05% |
356,305
-31,266
| -8% | -$2.06M |
|
406
Envista
NVST
$4.28B
| $23.2M | 0.05% |
+567,934
| New | +$21.6M |
|
|
LTHM
407
DELISTED
Livent Corporation
LTHM
| $23.2M | 0.05% |
1,065,993
+43,547
| +4% | +$1.01M |
|
408
iShares MSCI Emerging Markets ETF
EEM
$28B
| $23.1M | 0.05% |
+586,351
| New | +$23.3M |
|
|
409
PUT
Walmart Inc
WMT
$871B
| $23M | 0.05% |
468,000
-662,400
| -59% | -$31.4M |
|
410
Texas Roadhouse
TXRH
$12.7B
| $22.9M | 0.05% |
212,092
+67,235
| +46% | +$6.88M |
|
411
AtriCure
ATRC
$1.77B
| $22.9M | 0.05% |
+551,872
| New | +$22.9M |
|
412
Caterpillar
CAT
$409B
| $22.9M | 0.05% |
99,854
-7,475
| -7% | -$1.81M |
|
413
Abercrombie & Fitch
ANF
$4.17B
| $22.8M | 0.05% |
821,684
-420,386
| -34% | -$11.7M |
|
414
CALL
iShares US Real Estate ETF
IYR
$4.59B
| $22.7M | 0.05% |
267,900
+267,700
| +133,850% | +$23.4M |
|
415
Tyson Foods
TSN
$20.2B
| $22.7M | 0.05% |
382,572
-793,828
| -67% | -$48.7M |
|
416
CALL
KraneShares CSI China Internet ETF
KWEB
$5.2B
| $22.7M | 0.05% |
727,000
+371,000
| +104% | +$11.9M |
|
417
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$42.1B
| $22.6M | 0.05% |
174,200
+169,200
| +3,384% | +$22.1M |
|
418
Aflac
AFL
$63.9B
| $22.5M | 0.05% |
349,177
+149,408
| +75% | +$10.2M |
|
419
Ingersoll Rand
IR
$33B
| $22.5M | 0.05% |
387,154
+344,609
| +810% | +$19.4M |
|
420
Charter Communications
CHTR
$14.7B
| $22.5M | 0.05% |
62,784
-45,227
| -42% | -$16.9M |
|
421
Baker Hughes
BKR
$56.8B
| $22.4M | 0.05% |
776,654
+676,972
| +679% | +$20.5M |
|
422
Teradyne
TER
$54.8B
| $22.4M | 0.05% |
208,052
+171,997
| +477% | +$17.6M |
|
423
PUT
CVS Health
CVS
$137B
| $22.4M | 0.05% |
300,900
+232,000
| +337% | +$19.5M |
|
424
iShares Silver Trust
SLV
$28.1B
| $22.2M | 0.05% |
1,004,071
-127,129
| -11% | -$2.63M |
|
425
Manulife Financial
MFC
$72.6B
| $22.2M | 0.05% |
+1,209,005
| New | +$23M |
|
Similar funds
Marshall Wace's Q1 2023 Portfolio in Review
As of Q1 2023, Marshall Wace held 3,576 positions worth $47.1B, up 5.9% from $44.5B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Marshall Wace's Q1 2023 filing shows 705 new, 706 increased, 825 reduced and 988 closed positions. Its largest new stake was Madrigal Pharmaceuticals: 541,764 shares worth $131M. The largest sale was Cigna, an estimated $312M.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 16% a quarter earlier, followed by Technology and Consumer Discretionary.
- Marshall Wace's largest Q1 2023 buy was Madrigal Pharmaceuticals: 541,764 shares worth $131M.
- Marshall Wace added most to Walmart Inc in Q1 2023, an estimated $417M increase.
- Marshall Wace's biggest Q1 2023 reduction was Cigna, cutting an estimated $312M.
- Marshall Wace fully exited Merck in Q1 2023, selling an estimated $115M.
- Marshall Wace's ten largest holdings make up 14% of its $47.1B portfolio in Q1 2023.
- Marshall Wace opened 705 new positions and closed 988 in Q1 2023.
- Marshall Wace's portfolio value rose 5.9% quarter-over-quarter to $47.1B.
Based on Marshall Wace's 13F filing for Q1 2023, filed 15 May 2023.